Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases

• Published in: Gastroenterology and hepatology from bed to bench Vol. 9; no. 3; pp. 158 - 173
• Main Authors: Safaei, Akram, Arefi Oskouie, Afsaneh, Mohebbi, Seyed Reza, Rezaei-Tavirani, Mostafa, Mahboubi, Mohammad, Peyvandi, Maryam, Okhovatian, Farshad, Zamanian-Azodi, Mona
• Format: Journal Article
• Language: English
• Published: Iran Shaheed Beheshti University of Medical Sciences 2016
• Subjects: Review; Cirrhosis; Metabolomics; HCC; NAFLD; NASH
• ISSN: 2008-2258; 2008-4234

Metabolome analysis is used to evaluate the characteristics and interactions of low molecular weight metabolites under a specific set of conditions. In cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatotic hepatitis (NASH) the liver does not function thoroughly due to long-term damage. Unfortunately the early detection of cirrhosis, HCC, NAFLD and NASH is a clinical problem and determining a sensitive, specific and predictive novel method based on biomarker discovery is an important task. On the other hand, metabolomics has been reported as a new and powerful technology in biomarker discovery and dynamic field that cause global comprehension of system biology. In this review, it has been collected a heterogeneous set of metabolomics published studies to discovery of biomarkers in researches to introduce diagnostic biomarkers for early detection and the choice of patient-specific therapies.